NAARDEN, the Netherlands and MIAMI, Would possibly 01, 2026 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Corporate N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, scientific biopharmaceutical corporate creating oral, non-statin drugs for sufferers susceptible to heart problems (“CVD”) with increased low-density lipoprotein ldl cholesterol (“LDL-C”), for whom current remedies aren’t sufficiently efficient or well-tolerated, lately introduced that the Reimbursement Committee of NewAmsterdam’s Board of Administrators licensed the grant of inducement percentage choices masking an combination of fifty,400 of NewAmsterdam’s unusual stocks to 5 non-executive new hires. The proportion choices had been granted as an inducement subject material to the workers’ acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Corporate N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in line with Nasdaq List Rule 5635(c)(4).
The proportion choices have an workout worth according to percentage equivalent to $28.43, which represents the ultimate marketplace worth at the Nasdaq Inventory Marketplace of the Corporate’s unusual stocks on Would possibly 1, 2026, the grant date. The stocks topic to the choices will vest over 4 years, with 25% of the stocks vesting at the one-year anniversary of the appropriate vesting graduation date and the stability of the stocks vesting in a chain of 36 equivalent per thirty days installments thereafter, topic to every worker’s persevered carrier with NewAmsterdam on such vesting dates. The choices are topic to the phrases and stipulations of the 2024 Inducement Plan and the phrases and stipulations of an choice award settlement masking the grant.
The Reimbursement Committee of NewAmsterdam’s Board of Administrators additionally licensed the grant of limited inventory gadgets masking an combination of 15,400 of NewAmsterdam’s unusual stocks to 5 non-executive new hires. The limited inventory gadgets had been granted as an inducement subject material to the workers’ acceptance of employment with NewAmsterdam pursuant to the 2024 Inducement Plan and in line with Nasdaq List Rule 5635(c)(4).
The limited inventory gadgets had been granted on Would possibly 1, 2026. The limited inventory gadgets will vest over 3 years, with one-third of the limited inventory gadgets vesting on every of the one-year, two-year and three-year anniversaries of the appropriate vesting graduation date, topic to every worker’s persevered carrier with NewAmsterdam on such vesting dates. The limited inventory gadgets are topic to the phrases and stipulations of the 2024 Inducement Plan and the phrases and stipulations of a limited inventory unit award settlement masking the grant.
About NewAmsterdamNewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical corporate whose challenge is to toughen affected person care in populations with metabolic illnesses the place lately licensed remedies have now not been good enough or properly tolerated. We search to fill a vital unmet want for a secure, well-tolerated and handy LDL-lowering treatment. In a couple of segment 3 research, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, on my own or as a fixed-dose aggregate with ezetimibe, as LDL-C reducing remedies for use as an accessory to statin treatment for sufferers susceptible to CVD with increased LDL-C, for whom current remedies aren’t sufficiently efficient or properly tolerated.
